USFDA May 2026 ANDA Approvals & Landmark Supreme Court IP Ruling USFDA May 2026 ANDA Approvals & Landmark Supreme Court IP Ruling

Summary of the blog post - 2 minutes read

US Generic Pharma Update 2026: May ANDA Approvals & Landmark Supreme Court IP Ruling

The U.S. generic pharmaceutical sector experienced a highly active period in mid-2026, marked by a surge in regulatory clearances and a historic legal decision from the nation's highest court. In this comprehensive regulatory roundup, we break down the USFDA’s May 2026 Abbreviated New Drug Application (ANDA) approvals, highlight key product launches from top Indian manufacturers, and analyse a landmark Supreme Court patent decision that reshapes the legal landscape for generic drug entry.

1. USFDA May 2026 ANDA Approvals Analysis Overview

The USFDA maintained a high pace of regulatory reviews in May 2026, issuing a total of 65 ANDA approvals, of which 20 were tentative.

What is a Tentative Approval? A tentative approval indicates that a generic drug application has fully met all of the USFDA’s rigid scientific, quality, safety, and efficacy requirements. However, the product cannot be granted final marketing clearance or commercialised due to unexpired patents or market exclusivities held by the innovator brand-name drug.

Several global and India-based generic giants led the chart, securing multiple application approvals during the month:

Company	Total ANDA Approvals (Final & Tentative)
Sandoz	5
Dr. Reddy’s Laboratories Ltd	4
Zydus Pharmaceuticals	4
Accord BioPharma Inc.	3
Hetero Labs Limited	3
Micro Labs	3
Alembic Pharmaceuticals Limited	2
Caplin	2
Lupin	2

2. Key Product Highlights from Leading Indian Manufacturers

Several prominent Indian pharmaceutical firms secured highly strategic approvals in May 2026, targeting robust commercial segments in the U.S. healthcare market:

Ipca Laboratories: Propranolol Hydrochloride Extended-Release Capsules

• The Approval: Ipca secured a major nod for its generic version of the blockbuster brand Inderal LA across strengths of 60 mg, 80 mg, 120 mg, and 160 mg.

• Indications & Market: Aimed at chronic care prescriptions, this multi-million dollar segment currently has active generic sales estimated at $71 million in the U.S. Ipca will face fierce volume competition from established generic heavyweights, including Actavis (Teva), Zydus Pharmaceuticals, and New Jersey-based ANI Pharmaceuticals (the RLD holder).

Micro Labs: Torsemide Oral Tablets

• The Approval: Micro Labs cleared its 5 mg, 10 mg, and 20 mg oral tablets, targeting a $35 million U.S. market.

• Clinical Edge: Torsemide is a loop diuretic vital for treating edema related to congestive heart failure, chronic kidney disease, and liver cirrhosis. It holds a clear clinical advantage over first-generation options like furosemide due to a longer-lasting diuretic effect and highly predictable bioavailability. Micro Labs joins a highly competitive playing field alongside Teva, Aurobindo, Sun Pharma, and Hetero Labs.

Caplin Steriles: Calcium Gluconate Injection USP

• The Approval: Caplin received a vital sterile injectable nod for a 100 mg/mL concentration in hospital-aligned 10 mL, 50 mL, and 100 mL vials, acting as a direct generic equivalent to Fresenius Kabi's RLD.

• Clinical Edge & Value: Calcium Gluconate is an acute-care inpatient staple used to manage symptomatic hypocalcemia, hyperkalemia, and magnesium toxicity. Capturing market share in this $71 million therapeutic segment serves as an excellent aseptic compliance read for Caplin's Chennai-based facility, putting it in direct competition with Amneal and Gland Pharma.

Zydus Lifesciences: Hydrocortisone Sodium Succinate for Injection USP

• The Approval: Zydus secured approval for its $100\text{ mg/vial}$ formulation manufactured at its Vadodara facility in India, referencing Pfizer's Solu-Cortef.

• Market Significance: This highly soluble glucocorticoid is critical for rapid IV/IM administration in emergency settings for conditions like Addisonian crises, shock, and status asthmaticus. Zydus' entry helps stabilize a critical U.S. supply chain prone to historical shortages, competing for hospital and GPO volume with Cipla, Apotex, and Pfizer.

Mylan Laboratories (Viatris): Levetiracetam Injection

• The Approval: Mylan cleared its sterile intravenous formulations (500 mg/5 mL, 1 g/100 mL, and 1.5 g/100 mL) referencing UCB Pharma's Keppra Injection.

• Market Significance: Acting as an alternative adjunctive therapy for adult and pediatric seizure management when oral dosing isn't feasible, this hospital staple represents a market segment generating $19 million to $37 million in peak annual sales. Mylan will compete against specialised sterile competitors like Aurobindo, Sun Pharma, Hikma, and Gland Pharma.

3. SCOTUS Landmark Intellectual Property Ruling: Hikma v. Amarin

On June 4, 2026, the Supreme Court of the United States (SCOTUS) delivered a monumental, unanimous victory to the generic drug industry in the case Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc..

The Core of the Dispute

Amarin developed the pioneer drug Vascepa (icosapent ethyl), which held two FDA-approved indications: severe hypertriglyceridemia (SH indication) and a secondary, broader cardiovascular risk-reduction use (CV indication) protected by method-of-use patents.

Hikma utilised the Hatch-Waxman framework's Section viii statement to launch a "skinny label" generic version that intentionally carved out the patented CV indication while including the unpatented SH indication. Amarin sued, claiming Hikma's website descriptions, investor press releases, and patient leaflets actively induced doctors to prescribe the generic for the patented CV use.

The Supreme Court's Decision

Writing for the unanimous court, Justice Jackson reversed a previous Federal Circuit decision, confirming that Amarin failed to state a valid claim of active inducement under 35 U.S.C. § 271(b). The court clarified that establishing liability requires plausible allegations of affirmative, purposeful steps to encourage infringement—not how a passive audience might interpret vague public statements or standard commercial phrases.

The Supreme Court dismantled the brand-name manufacturer's arguments across three core findings:

1. Statutory Sameness is Protected: Generic labels are legally mandated to be nearly identical to the brand-name label (the "duty of sameness"). Describing a drug using standard industry phrasing like "generic equivalent" cannot be used as evidence of illegal intent.

2. Omissions are Not Inducement: Active inducement requires an explicit action. Failing to clarify that an approval is limited to a single indication in a press release does not constitute an active step toward promoting infringement.

3. Financial Disclosures are for Investors, Not Doctors: Touting historical brand sales to financial analysts on an investor call requires a highly speculative chain of logic to count as clinician inducement.

Why This Matters for the Generic Industry

This landmark ruling provides massive relief and operational certainty to generic drug developers using skinny-labeling strategies. By safely protecting Section viii carve-outs from aggressive brand lawsuits, the decision ensures generic companies can launch affordable medicines much faster, avoiding long, costly legal delays at product launch. 

-------------xx--------------xx------------------

I encourage you to read the detailed post below. 

Contents

ANDA approvals-May 2026

General information

Biogen To Pay ₹162 Crore To Settle Investor Lawsuit Over Alzheimer’s Drug Aduhelm

Stevanato Group launches pen injector platform targeting GLP-1, obesity drug market

Intellectual Property

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

ANDA approvals-May 2026

We follow ANDA approvals.

In May 2026, the USFDA issued 65 ANDA approvals, of which 20 were tentative. 

A tentative approval is a formal notification from the USFDA indicating that a generic drug application has met all scientific and regulatory requirements for safety, efficacy, and quality, but cannot be granted final marketing approval due to unexpired patents or market exclusivities held by the original brand-name drug.

The companies that could seek more than two ANDA approvals (including tentative ones) in May were as follows. 

Some of our other comments about a few ANDA approvals sought by Indian companies are listed below

General information

Biogen To Pay ₹162 Crore To Settle Investor Lawsuit Over Alzheimer’s Drug Aduhelm

U.S.-based biotechnology company Biogen has agreed to pay approximately ₹162 crore, or $18.9 million, to settle a securities class-action lawsuit filed by investors over its Alzheimer’s drug Aduhelm. The lawsuit alleged that the company misled shareholders about the drug’s commercial prospects, market readiness and expected insurance coverage.

The proposed settlement has been filed in a federal court in Massachusetts and will require court approval before it becomes final. If approved, it will end litigation that has been pending since 2022.

News here

Stevanato Group launches pen injector platform targeting GLP-1, obesity drug market

Deora uses a pull-push workflow that sets a fixed dose then injects, minimizing steps and lowering the likelihood of dosing errors during repeated administrations.

Compatibility with 1.5 mL and 3 mL cartridges enables fixed-dose volumes up to 0.75 mL, supporting incretin regimens while leveraging established primary packaging formats.

Modular design is intended to span multiple fixed-dose configurations with minimal engineering changes, helping manufacturers scale device supply without major alterations to existing fill-finish workflows.

Distribution of evaluation units to pharmaceutical partners signals near-term development programs, with production planning aligned to future commercialization alongside the company’s Alina and Aidaptus platforms.

News here

Intellectual Property 

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

Executive Summary

The Supreme Court of the United States unanimously reversed a Federal Circuit decision, ruling that Amarin Pharma, Inc. failed to state a claim of active inducement against generic manufacturer Hikma Pharmaceuticals USA Inc. The Court clarified that standard pleading requirements for induced patent infringement under 35 U.S.C. §271(b) demand plausible allegations of affirmative, purposeful steps to encourage infringement. Simply showing that healthcare providers might interpret a generic manufacturer's public statements or labels as encouragement is insufficient to establish liability. (Docket No. 24-889 | Argued: April 29, 2026 | Decided: June 4, 2026 )

Background of the Dispute

Amarin developed the pioneer drug Vascepa, containing the active ingredient icosapent ethyl. The FDA initially approved Vascepa in 2012 for the treatment of severe hypertriglyceridemia (SH indication). In 2019, the FDA approved a second, broader use for Vascepa: reducing cardiovascular risk in patients with hypertriglyceridemia who are concurrently taking statins (CV indication). Amarin secured two method-of-use patents protecting this secondary CV indication. 

In 2016, Hikma submitted an ANDA to market generic icosapent ethyl. After a district court invalidated Amarin’s original SH-indication patents, Hikma utilised the Hatch-Waxman framework's section viii statement. It sought approval for a skinny label that excluded the still-patented CV indication, while including the unpatented SH indication. The FDA approved Hikma’s generic application in 2020, assigning it an AB therapeutic equivalence rating. 

Amarin subsequently filed suit in the District of Delaware, claiming Hikma actively induced patent infringement. Amarin argued that the totality of Hikma’s marketing materials, spanning its label omissions, website descriptions, patient leaflets, and investor press releases, encouraged doctors to prescribe the generic for the patented CV indication. The District Court dismissed the complaint for failure to state a claim. However, the Federal Circuit reversed, holding that it was at least plausible that a physician could read Hikma's collective statements as instruction or encouragement to infringe. 

The Supreme Court's Legal Analysis

Justice Jackson emphasised that the Federal Circuit applied an incorrect legal standard. The core inquiry under §271(b) is whether the defendant actively and affirmatively encouraged infringing use, not how an audience might passively interpret vague phrasing. 

An induced-infringement claim requires three elements: 

1. direct infringement by a third party, 

2. knowledge that the induced acts constitute infringement, and 

3. active steps taken to encourage the infringement. 

Because Hikma only disputed the third element, the Court evaluated Hikma’s statements through the lens of purposeful, culpable expression and conduct. 

The Court dismantled Amarin's multi-layered inducement arguments across three distinct categories:

1. Statutory Sameness and Normal Industry Practice

Several of Hikma's contested actions had obvious alternative explanations: standard industry practices and compliance with federal regulations. Hikma’s label omitted the CV Limitation of Use and retained information regarding a clinical study because generic labels are legally mandated to be identical to the brand-name label (duty of sameness). Additionally, Hikma's pre-launch press releases describing its product as a generic equivalent of Vascepa constitute standard, truthful industry language and cannot serve as evidence of illegal intent. 

2. Impermissibility of Omissions

The Court ruled that active inducement requires affirmative actions, meaning Amarin could not rely on mere omissions, inactions, or nonfeasance. The fact that Hikma's press releases failed to explicitly clarify that its approval was limited to the SH indication does not constitute an active step toward promoting patent infringement. 

3. Vague Phrases and Attenuated Speculation

The remaining statements highlighted by Amarin were determined to be far too vague or roundabout to support liability: 

• Patient Leaflet: Warnings regarding cardiovascular side effects and standard disclaimers about off-label prescribing are passive, protective disclosures, not active invitations to infringe. 
• Website Disclosures: Describing the broad therapeutic category as "hypertriglyceridemia" and noting an "AB" rating are standard product features. Furthermore, Hikma’s website explicitly stated that its product was indicated for fewer uses than Vascepa’s approved uses. 
• Investor Press Releases: Touting total historical sales numbers for Vascepa was directed at financial investors, not clinicians. Relying on doctors’ reading investor materials to find subtle encouragement requires an impermissibly speculative chain of events. 

Conclusion

The Supreme Court concluded that while Amarin's theoretical chain of events was technically possible, it failed to cross the threshold into a plausible scenario of active inducement. To rule otherwise would punish generic manufacturers for following federal law and severely disrupt regular commercial product distribution. The Court reversed the Federal Circuit's judgment and remanded the case for further proceedings.

This landmark Supreme Court ruling provides clear guidance and relief to the US generic pharmaceutical industry, especially for companies using the skinny-labelling strategy. By confirming that a generic company cannot be held liable for induced infringement based on standard regulatory compliance or vague public statements, the Court has effectively protected the section viii carve-out from problematic brand lawsuits. Generic manufacturers no longer need to worry that mandatory label similarities, industry terms like generic equivalent, or investor sales data will be misinterpreted as evidence of intent to infringe. This significantly reduces the risk of costly, lengthy lawsuits at product launch, giving businesses greater operational certainty and legal flexibility. Ultimately, by safeguarding the Hatch-Waxman framework, this decision helps more affordable generics enter the US healthcare market more easily and quickly, avoiding unnecessary legal delays.

Decision here

#PharmaNews, #USFDA, #GenericDrugs, #IPLaw, #SCOTUS, #Biopharma, #RegulatoryAffairs, #HatchWaxman